{ "schemaVersion": 1, "organisationId": "O-86cc7f1465bc427e8294b463a9b6382d", "slug": "fresenius", "name": "FRESENIUS", "updatedAt": "2026-03-19T22:20:48.169048Z", "sections": [ { "type": "OVERVIEW", "text": "Fresenius is a global healthcare company whose activities are centered on healthcare services and healthcare products. Its stated mission, “Committed to life,” emphasizes patient health and well-being, with a focus on saving and improving lives through affordable, innovative medical products and high-quality clinical care. The group’s two main operating businesses are Fresenius Helios, Europe’s leading private hospital operator, and Fresenius Kabi, which supplies products for critically and chronically ill patients including biopharmaceuticals, clinical nutrition, MedTech products, generic IV drugs, and IV fluids. Healthcare services account for around 60% of sales and healthcare products around 40%. [P-38441ba71d934e3caa1995148c0f0964][P-9439b9272c5848cab16e93c002454a76][P-27cdb1b411fb4bd180e51f49066ae913][P-8238362b84804f11859de6d2b2778cb2]\n\nFresenius has been operating for more than 100 years and has a broad international footprint, with subsidiaries in more than 60 countries, an international sales network, more than 50 production sites, and more than 130 hospitals. Its hospital business is anchored in Germany and Spain through Helios, while its products business gives it a global presence across acute and chronic care markets. In 2024, Fresenius reported revenue of €21.526 billion and employed 176,486 people. [P-38441ba71d934e3caa1995148c0f0964][P-c7a9f5b0bc8845debf584329e8d9c551][P-ac74553b1e194ea49848d9779a26ec79][T-e2c302b294614ffe950fa8e1b81f947d]\n[P-38441ba71d934e3caa1995148c0f0964][P-9439b9272c5848cab16e93c002454a76][P-27cdb1b411fb4bd180e51f49066ae913][P-8238362b84804f11859de6d2b2778cb2][P-c7a9f5b0bc8845debf584329e8d9c551][P-ac74553b1e194ea49848d9779a26ec79][T-e2c302b294614ffe950fa8e1b81f947d]", "updatedAt": "2026-03-19T22:20:48.169048Z" }, { "type": "PRODUCTS", "text": "Fresenius’ main product portfolio sits in Fresenius Kabi, which focuses on biopharmaceuticals, clinical nutrition, MedTech, generic IV drugs and IV fluids for critically and chronically ill patients.[P-af5752a734c442a18cfd34b66f72b6f7] In biopharma, named products include Tyenne, a tocilizumab biosimilar approved in both intravenous and subcutaneous formulations, and Stimufend, a pegfilgrastim biosimilar used for patients who develop neutropenia after chemotherapy.[P-f23ce612013241829a12bec6ce09270c][P-db4ae891e525433e953d3075737a870d] In clinical nutrition, Fresenius Kabi develops parenteral formulations tailored to specific patient groups and uses multi-chamber bags intended to be safer and more convenient in hospital and home-care settings; its enteral range includes the Fresubin plant-based drink, and its parenteral portfolio includes fish-oil-containing nutrition products aimed at improving clinical outcomes and potentially shortening ICU and hospital stays.[P-cf4ea90991e84d85a3deac60dcf2ef71][P-70145ff0a31c45e58c8fe868714b5e52][P-3dfebc63c6bf42dfbfa7d836aa0f81f4][P-62b9853381a946c7af79de9bebcbf73a] In IV drugs and fluids, the company reports more than 100 active generic drug projects, including work on new formulations, dosage forms and primary packaging; examples include Lacosamide for epilepsy in intensive care medicine, basic infusion solutions made up primarily of electrolytes, carbohydrates and water, balanced solutions for acid-base and electrolyte management, and blood-volume substitution solutions containing hydroxyethyl starch derived from waxy maize.[P-5ce4f0a8c438466d9767b097456b279e][P-92fdb0dcb1ed40afb207f5591614d76e][P-ca1011200e5d48d18554bbeffbfe069f][P-aa10d1a90f8d4f278aa38e119c340a77] The container and delivery formats include KabiPac plastic bottles and freeflex infusion bags that are non-PVC and non-DEHP and use resealable injection and infusion ports, with increasing use of data-matrix codes.[P-3b61dbae12314e39b7ba035e30437e56]\n\nFresenius Kabi’s MedTech offering includes infusion and nutrition pumps, dedicated and non-dedicated disposables, software for application safety, workflow and interoperability with hospital systems, plus anesthesia monitoring devices and sensors.[P-2d2b666e3ee546349fc4b8ca1d08319a] Named platforms include the Ivenix infusion system, designed to be easier to use than conventional systems and to increase infusion safety, with more than 10,000 Ivenix Large Volume Pumps reported in use in the United States.[P-e4fedd72977d4aa1b4b454ff9b20c02b][P-964d7896e24343b8809f2a75e4502b66] In transfusion medicine and cell therapies, Fresenius Kabi offers Aurora Xi disposables for plasma collection, Comtec sets for therapeutic apheresis, LOVO for automated cell washing and concentration in a fully closed system, CUE for automated processing of small volumes, and the Amicus Blue system with the Phelix light box for extracorporeal photopheresis.[P-6a1504636db14815aa55b4dffcc531cc][P-d553ebafdee2448c9334c2257b62cba5][P-27b66d0925af4679bbf8a2015238e60f][P-abbf5a8bb507404d8f3b7fde5aebee82][P-52b6a9891f7a482b9b8fc4abc19cb20d] On the services side, Fresenius Helios provides in- and outpatient clinical care through hospital, medical care center, outpatient health center, occupational health and prevention networks, while Vamed’s rehabilitation activities include specialized services in prevention, acute care, nursing, and inpatient and outpatient rehabilitation, alongside digital rehabilitation services.[P-89e2d39d2a0c487f8352d12f406df29c][https://www.fresenius.com/inpatient-and-outpatient-treatments][P-11fc4c3eb68b42c993b8a6d7428143eb][P-4db740ed46bd48bf9e2fcbbd92f795ba] In 2024, Fresenius reported €8,154 million of revenue from products and related services at Kabi and €12,703 million of revenue from services at Helios, indicating that the group’s performance is primarily driven by Kabi’s product portfolio and Helios’ care delivery services.[P-cb3fef5e0112403a80ff018c553624f2][T-c930eaeb053a4335abcd74582c448365]\n[P-af5752a734c442a18cfd34b66f72b6f7][P-f23ce612013241829a12bec6ce09270c][P-db4ae891e525433e953d3075737a870d][P-cf4ea90991e84d85a3deac60dcf2ef71][P-70145ff0a31c45e58c8fe868714b5e52][P-3dfebc63c6bf42dfbfa7d836aa0f81f4][P-62b9853381a946c7af79de9bebcbf73a][P-5ce4f0a8c438466d9767b097456b279e][P-92fdb0dcb1ed40afb207f5591614d76e][P-ca1011200e5d48d18554bbeffbfe069f][P-aa10d1a90f8d4f278aa38e119c340a77][P-3b61dbae12314e39b7ba035e30437e56][P-2d2b666e3ee546349fc4b8ca1d08319a][P-e4fedd72977d4aa1b4b454ff9b20c02b][P-964d7896e24343b8809f2a75e4502b66][P-6a1504636db14815aa55b4dffcc531cc][P-d553ebafdee2448c9334c2257b62cba5][P-27b66d0925af4679bbf8a2015238e60f][P-abbf5a8bb507404d8f3b7fde5aebee82][P-52b6a9891f7a482b9b8fc4abc19cb20d][P-89e2d39d2a0c487f8352d12f406df29c][P-11fc4c3eb68b42c993b8a6d7428143eb][P-4db740ed46bd48bf9e2fcbbd92f795ba][P-cb3fef5e0112403a80ff018c553624f2][T-c930eaeb053a4335abcd74582c448365][https://www.fresenius.com/inpatient-and-outpatient-treatments]", "updatedAt": "2026-03-19T22:20:48.169048Z" }, { "type": "GEOGRAPHY", "text": "Fresenius is headquartered in Bad Homburg, Germany, and operates in more than 60 countries through subsidiaries and an international sales network; its overall footprint includes more than 50 production sites and more than 130 hospitals.[P-9c25a348ed3a4647b98521bce6b214a4][P-c7a9f5b0bc8845debf584329e8d9c551] For internal regional reporting, the company groups its activities into Germany, Europe excluding Germany, North America, Asia Pacific, Latin America, and Africa.[P-233601ad634a4955a7232327a182a55a] Revenue is heavily concentrated in Europe: in 2024, Fresenius reported €15.662 billion of revenue in Europe, €2.701 billion in North America, €1.603 billion in Asia-Pacific, €1.404 billion in Latin America, and €156 million in Africa, on total revenue of €21.526 billion.[P-808f995289e9424f8d13dccbdbc2a818]\n\nIts workforce is also concentrated in Europe. In 2024, Fresenius reported 144,836 employees in Europe, including 86,101 in Germany and 58,735 in the rest of Europe, compared with 4,646 in North America, 9,847 in Asia-Pacific, 19,327 in Latin America, and 1,228 in Africa.[P-b5fe4e2345d24a06815c244282e6aaf9] Germany and Spain were the only countries with more than 10% of total headcount; other countries such as Colombia, the Dominican Republic, and China were each below that threshold.[P-525ac2025f4a4648800b8bc87ed524a5] Within healthcare services, Fresenius Helios is centered on Germany and Spain, with more than 80 hospitals in Germany and 50 in Spain at the end of 2024, plus 7 hospitals in Latin America.[P-89e2d39d2a0c487f8352d12f406df29c]\n[P-9c25a348ed3a4647b98521bce6b214a4][P-c7a9f5b0bc8845debf584329e8d9c551][P-233601ad634a4955a7232327a182a55a][P-808f995289e9424f8d13dccbdbc2a818][P-b5fe4e2345d24a06815c244282e6aaf9][P-525ac2025f4a4648800b8bc87ed524a5][P-89e2d39d2a0c487f8352d12f406df29c]", "updatedAt": "2026-03-19T22:20:48.169048Z" }, { "type": "SEGMENTS", "text": "In 2024 reporting, Fresenius is organized primarily around two operating companies: Fresenius Kabi and Fresenius Helios; discontinued Fresenius Vamed operations are excluded from segment reporting except for net income, and Vamed has not been a reporting segment since Q2 2024.[P-e7136859b0e94b418a2a88c23af1bf62][P-27eda82a57c84208b90069ae35b64460] Fresenius Kabi focuses on products for the therapy and care of critically and chronically ill patients, spanning biopharmaceuticals, clinical nutrition, MedTech, generic IV drugs and IV fluids.[P-27cdb1b411fb4bd180e51f49066ae913] Fresenius Helios is the hospital and care-services platform, described as providing healthcare services along the care continuum / “Care Provision Platform”; it includes Helios Germany and Helios Spain, with hospital, outpatient, occupational health and diagnostics activities.[P-7b1ad148aa264f528efcf4c4b5c4ae04][P-71bcc1f2263743efa0d4215d0256111d][P-0c554adf5f22485eb8a5da5a5e9b85f0] On the 2024 consolidated segment-reporting view, Kabi generated €8.4 billion of revenue and Helios €12.7 billion, against group revenue of €21.8 billion, implying an approximate revenue mix of 39% Kabi, 58% Helios, and 3% other/corporate items.[T-8959fe0564544e38846d031e4d1cde56]\n\nFresenius has also recently reported a broader three-segment structure. In 2023, reported revenue was €8.0 billion for Kabi, €12.3 billion for Helios, and €2.4 billion for Vamed; this equated to roughly 36%, 55%, and 9% of group sales, respectively.[T-abb1b0ec391f4458bf60128a8abd51fe] In that structure, Vamed focused on projects and services for hospitals and other healthcare facilities across the value chain, from development and planning through turnkey construction, maintenance, technical management, and operational management, and it was organized across High-End Services, Health Facility Operations, and Health Tech Engineers.[P-27eda82a57c84208b90069ae35b64460]\n[P-e7136859b0e94b418a2a88c23af1bf62][P-27eda82a57c84208b90069ae35b64460][P-27cdb1b411fb4bd180e51f49066ae913][P-7b1ad148aa264f528efcf4c4b5c4ae04][P-71bcc1f2263743efa0d4215d0256111d][P-0c554adf5f22485eb8a5da5a5e9b85f0][T-8959fe0564544e38846d031e4d1cde56][T-abb1b0ec391f4458bf60128a8abd51fe]", "updatedAt": "2026-03-19T22:20:48.169048Z" }, { "type": "HISTORY", "text": "Fresenius traces its roots to the Hirsch Pharmacy in Frankfurt, which opened in 1462, but the modern company began in 1912 when pharmacist Dr. Eduard Fresenius expanded the pharmacy’s laboratory into the pharmaceutical company Dr. E. Fresenius.[https://www.fresenius.com/history] In 1933, the manufacturing business was separated from the pharmacy and moved to Bad Homburg.[https://www.fresenius.com/history] After Eduard Fresenius died in 1946, his foster daughter Else Kröner remained at the helm of the company for many years, first as Managing Director and later as Chairwoman of the Supervisory Board.[https://www.fresenius.com/100YearsOfElseKroener] The company was converted into Fresenius AG at the end of 1981, and in 1983 Else Kröner established the Else Kröner-Fresenius Foundation, which became her sole heir after her death in 1988.[https://www.fresenius.com/faq][https://www.fresenius.com/else-kro%C3%B6ner-fresenius-foundation]\n\nA major structural milestone came in 1996, when Fresenius merged its dialysis business with National Medical Care to form Fresenius Medical Care, which was listed in Frankfurt and New York that year.[https://www.fresenius.com/node/5193][https://www.fresenius.com/node/4943] Fresenius then expanded through a series of larger acquisitions, including APP Pharmaceuticals in 2008, which gave Fresenius Kabi a significant position in the U.S. I.V. generics market.[https://www.fresenius.com/node/4798][https://www.fresenius.com/node/4351] In 2014, Helios completed the staged acquisition of hospitals and outpatient facilities from Rhön-Klinikum.[https://www.fresenius.com/node/4260][https://www.fresenius.com/node/4458] Fresenius further expanded its European hospital operations with the acquisition of Spain’s Quirónsalud, announced in 2016 and closed in early 2017.[https://www.fresenius.com/node/4941][P-cea20e0e1ffb4e19b298ca33e40bb33d]\n[P-cea20e0e1ffb4e19b298ca33e40bb33d][https://www.fresenius.com/history][https://www.fresenius.com/100YearsOfElseKroener][https://www.fresenius.com/faq][https://www.fresenius.com/else-kro%C3%B6ner-fresenius-foundation][https://www.fresenius.com/node/5193][https://www.fresenius.com/node/4943][https://www.fresenius.com/node/4798][https://www.fresenius.com/node/4351][https://www.fresenius.com/node/4260][https://www.fresenius.com/node/4458][https://www.fresenius.com/node/4941]", "updatedAt": "2026-03-19T22:20:48.169048Z" } ], "sources": [ { "id": "P-38441ba71d934e3caa1995148c0f0964", "href": "https://app.finbar.com/go?id=P-38441ba71d934e3caa1995148c0f0964", "label": "FRESENIUS — Full financial report (2024 Y), p2", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 2 }, { "id": "P-9439b9272c5848cab16e93c002454a76", "href": "https://app.finbar.com/go?id=P-9439b9272c5848cab16e93c002454a76", "label": "FRESENIUS — Full financial report (2024 Y), p157", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 157 }, { "id": "P-27cdb1b411fb4bd180e51f49066ae913", "href": "https://app.finbar.com/go?id=P-27cdb1b411fb4bd180e51f49066ae913", "label": "FRESENIUS — Full financial report (2024 Y), p313", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 313 }, { "id": "P-8238362b84804f11859de6d2b2778cb2", "href": "https://app.finbar.com/go?id=P-8238362b84804f11859de6d2b2778cb2", "label": "FRESENIUS — Full financial report (2024 Y), p157", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 157 }, { "id": "P-c7a9f5b0bc8845debf584329e8d9c551", "href": "https://app.finbar.com/go?id=P-c7a9f5b0bc8845debf584329e8d9c551", "label": "FRESENIUS — Full financial report (2024 Y), p158", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 158 }, { "id": "P-ac74553b1e194ea49848d9779a26ec79", "href": "https://app.finbar.com/go?id=P-ac74553b1e194ea49848d9779a26ec79", "label": "FRESENIUS — Full financial report (2024 Y), p85", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 85 }, { "id": "T-e2c302b294614ffe950fa8e1b81f947d", "href": "https://app.finbar.com/go?id=T-e2c302b294614ffe950fa8e1b81f947d", "label": "FRESENIUS — Full financial report (2024 Y), p3", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 3 }, { "id": "P-af5752a734c442a18cfd34b66f72b6f7", "href": "https://app.finbar.com/go?id=P-af5752a734c442a18cfd34b66f72b6f7", "label": "FRESENIUS — Full financial report (2024 Y), p132", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 132 }, { "id": "P-f23ce612013241829a12bec6ce09270c", "href": "https://app.finbar.com/go?id=P-f23ce612013241829a12bec6ce09270c", "label": "FRESENIUS — Full financial report (2024 Y), p100", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 100 }, { "id": "P-db4ae891e525433e953d3075737a870d", "href": "https://app.finbar.com/go?id=P-db4ae891e525433e953d3075737a870d", "label": "FRESENIUS — Full financial report (2023 Y), p44", "documentId": "D-cfec8f1abb2844e195383b43486b7734", "page": 44 }, { "id": "P-cf4ea90991e84d85a3deac60dcf2ef71", "href": "https://app.finbar.com/go?id=P-cf4ea90991e84d85a3deac60dcf2ef71", "label": "FRESENIUS — Full financial report (2024 Y), p100", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 100 }, { "id": "P-70145ff0a31c45e58c8fe868714b5e52", "href": "https://app.finbar.com/go?id=P-70145ff0a31c45e58c8fe868714b5e52", "label": "FRESENIUS — Full financial report (2024 Y), p100", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 100 }, { "id": "P-3dfebc63c6bf42dfbfa7d836aa0f81f4", "href": "https://app.finbar.com/go?id=P-3dfebc63c6bf42dfbfa7d836aa0f81f4", "label": "FRESENIUS — Full financial report (2024 Y), p101", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 101 }, { "id": "P-62b9853381a946c7af79de9bebcbf73a", "href": "https://app.finbar.com/go?id=P-62b9853381a946c7af79de9bebcbf73a", "label": "FRESENIUS — Full financial report (2024 Y), p100", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 100 }, { "id": "P-5ce4f0a8c438466d9767b097456b279e", "href": "https://app.finbar.com/go?id=P-5ce4f0a8c438466d9767b097456b279e", "label": "FRESENIUS — Full financial report (2024 Y), p102", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 102 }, { "id": "P-92fdb0dcb1ed40afb207f5591614d76e", "href": "https://app.finbar.com/go?id=P-92fdb0dcb1ed40afb207f5591614d76e", "label": "FRESENIUS — Full financial report (2024 Y), p10", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 10 }, { "id": "P-ca1011200e5d48d18554bbeffbfe069f", "href": "https://app.finbar.com/go?id=P-ca1011200e5d48d18554bbeffbfe069f", "label": "FRESENIUS — Full financial report (2024 Y), p102", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 102 }, { "id": "P-aa10d1a90f8d4f278aa38e119c340a77", "href": "https://app.finbar.com/go?id=P-aa10d1a90f8d4f278aa38e119c340a77", "label": "FRESENIUS — Full financial report (2024 Y), p102", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 102 }, { "id": "P-3b61dbae12314e39b7ba035e30437e56", "href": "https://app.finbar.com/go?id=P-3b61dbae12314e39b7ba035e30437e56", "label": "FRESENIUS — Full financial report (2024 Y), p102", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 102 }, { "id": "P-2d2b666e3ee546349fc4b8ca1d08319a", "href": "https://app.finbar.com/go?id=P-2d2b666e3ee546349fc4b8ca1d08319a", "label": "FRESENIUS — Full financial report (2024 Y), p108", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 108 }, { "id": "P-e4fedd72977d4aa1b4b454ff9b20c02b", "href": "https://app.finbar.com/go?id=P-e4fedd72977d4aa1b4b454ff9b20c02b", "label": "FRESENIUS — Full financial report (2024 Y), p89", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 89 }, { "id": "P-964d7896e24343b8809f2a75e4502b66", "href": "https://app.finbar.com/go?id=P-964d7896e24343b8809f2a75e4502b66", "label": "FRESENIUS — Full financial report (2024 Y), p10", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 10 }, { "id": "P-6a1504636db14815aa55b4dffcc531cc", "href": "https://app.finbar.com/go?id=P-6a1504636db14815aa55b4dffcc531cc", "label": "FRESENIUS — Full financial report (2024 Y), p125", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 125 }, { "id": "P-d553ebafdee2448c9334c2257b62cba5", "href": "https://app.finbar.com/go?id=P-d553ebafdee2448c9334c2257b62cba5", "label": "FRESENIUS — Full financial report (2024 Y), p108", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 108 }, { "id": "P-27b66d0925af4679bbf8a2015238e60f", "href": "https://app.finbar.com/go?id=P-27b66d0925af4679bbf8a2015238e60f", "label": "FRESENIUS — Full financial report (2024 Y), p412", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 412 }, { "id": "P-abbf5a8bb507404d8f3b7fde5aebee82", "href": "https://app.finbar.com/go?id=P-abbf5a8bb507404d8f3b7fde5aebee82", "label": "FRESENIUS — Full financial report (2024 Y), p278", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 278 }, { "id": "P-52b6a9891f7a482b9b8fc4abc19cb20d", "href": "https://app.finbar.com/go?id=P-52b6a9891f7a482b9b8fc4abc19cb20d", "label": "FRESENIUS — Full financial report (2024 Y), p101", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 101 }, { "id": "P-89e2d39d2a0c487f8352d12f406df29c", "href": "https://app.finbar.com/go?id=P-89e2d39d2a0c487f8352d12f406df29c", "label": "FRESENIUS — Full financial report (2024 Y), p313", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 313 }, { "id": "https://www.fresenius.com/inpatient-and-outpatient-treatments", "href": "https://www.fresenius.com/inpatient-and-outpatient-treatments", "label": "www.fresenius.com" }, { "id": "P-11fc4c3eb68b42c993b8a6d7428143eb", "href": "https://app.finbar.com/go?id=P-11fc4c3eb68b42c993b8a6d7428143eb", "label": "FRESENIUS — Full financial report (2024 Q 3), p49", "documentId": "D-ea681267a28c4ed59ff4042e4a00c165", "page": 49 }, { "id": "P-4db740ed46bd48bf9e2fcbbd92f795ba", "href": "https://app.finbar.com/go?id=P-4db740ed46bd48bf9e2fcbbd92f795ba", "label": "FRESENIUS — Full financial report (2023 Y), p140", "documentId": "D-cfec8f1abb2844e195383b43486b7734", "page": 140 }, { "id": "P-cb3fef5e0112403a80ff018c553624f2", "href": "https://app.finbar.com/go?id=P-cb3fef5e0112403a80ff018c553624f2", "label": "FRESENIUS — Full financial report (2024 Y), p337", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 337 }, { "id": "T-c930eaeb053a4335abcd74582c448365", "href": "https://app.finbar.com/go?id=T-c930eaeb053a4335abcd74582c448365", "label": "FRESENIUS — Full financial report (2024 Y), p337", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 337 }, { "id": "P-9c25a348ed3a4647b98521bce6b214a4", "href": "https://app.finbar.com/go?id=P-9c25a348ed3a4647b98521bce6b214a4", "label": "FRESENIUS — Full financial report (2024 Y), p416", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 416 }, { "id": "P-233601ad634a4955a7232327a182a55a", "href": "https://app.finbar.com/go?id=P-233601ad634a4955a7232327a182a55a", "label": "FRESENIUS — Full financial report (2024 Y), p230", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 230 }, { "id": "P-808f995289e9424f8d13dccbdbc2a818", "href": "https://app.finbar.com/go?id=P-808f995289e9424f8d13dccbdbc2a818", "label": "FRESENIUS — Full financial report (2024 Y), p115", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 115 }, { "id": "P-b5fe4e2345d24a06815c244282e6aaf9", "href": "https://app.finbar.com/go?id=P-b5fe4e2345d24a06815c244282e6aaf9", "label": "FRESENIUS — Full financial report (2024 Y), p230", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 230 }, { "id": "P-525ac2025f4a4648800b8bc87ed524a5", "href": "https://app.finbar.com/go?id=P-525ac2025f4a4648800b8bc87ed524a5", "label": "FRESENIUS — Full financial report (2024 Y), p230", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 230 }, { "id": "P-e7136859b0e94b418a2a88c23af1bf62", "href": "https://app.finbar.com/go?id=P-e7136859b0e94b418a2a88c23af1bf62", "label": "FRESENIUS — Full financial report (2024 Y), p311", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 311 }, { "id": "P-27eda82a57c84208b90069ae35b64460", "href": "https://app.finbar.com/go?id=P-27eda82a57c84208b90069ae35b64460", "label": "FRESENIUS — Full financial report (2024 Y), p84", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 84 }, { "id": "P-7b1ad148aa264f528efcf4c4b5c4ae04", "href": "https://app.finbar.com/go?id=P-7b1ad148aa264f528efcf4c4b5c4ae04", "label": "FRESENIUS — Full financial report (2024 Y), p84", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 84 }, { "id": "P-71bcc1f2263743efa0d4215d0256111d", "href": "https://app.finbar.com/go?id=P-71bcc1f2263743efa0d4215d0256111d", "label": "FRESENIUS — Full financial report (2024 Y), p84", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 84 }, { "id": "P-0c554adf5f22485eb8a5da5a5e9b85f0", "href": "https://app.finbar.com/go?id=P-0c554adf5f22485eb8a5da5a5e9b85f0", "label": "FRESENIUS — Full financial report (2024 Y), p84", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 84 }, { "id": "T-8959fe0564544e38846d031e4d1cde56", "href": "https://app.finbar.com/go?id=T-8959fe0564544e38846d031e4d1cde56", "label": "FRESENIUS — Full financial report (2024 Y), p310", "documentId": "D-c012d71ddf124252805247be2a9f4c40", "page": 310 }, { "id": "T-abb1b0ec391f4458bf60128a8abd51fe", "href": "https://app.finbar.com/go?id=T-abb1b0ec391f4458bf60128a8abd51fe", "label": "FRESENIUS — Full financial report (2023 Y), p269", "documentId": "D-cfec8f1abb2844e195383b43486b7734", "page": 269 }, { "id": "https://www.fresenius.com/history", "href": "https://www.fresenius.com/history", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/100YearsOfElseKroener", "href": "https://www.fresenius.com/100YearsOfElseKroener", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/faq", "href": "https://www.fresenius.com/faq", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/else-kro%C3%B6ner-fresenius-foundation", "href": "https://www.fresenius.com/else-kro%C3%B6ner-fresenius-foundation", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/5193", "href": "https://www.fresenius.com/node/5193", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4943", "href": "https://www.fresenius.com/node/4943", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4798", "href": "https://www.fresenius.com/node/4798", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4351", "href": "https://www.fresenius.com/node/4351", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4260", "href": "https://www.fresenius.com/node/4260", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4458", "href": "https://www.fresenius.com/node/4458", "label": "www.fresenius.com" }, { "id": "https://www.fresenius.com/node/4941", "href": "https://www.fresenius.com/node/4941", "label": "www.fresenius.com" }, { "id": "P-cea20e0e1ffb4e19b298ca33e40bb33d", "href": "https://app.finbar.com/go?id=P-cea20e0e1ffb4e19b298ca33e40bb33d", "label": "FRESENIUS — Press release (2016 Y), p10", "documentId": "D-083564b33a6644708039954bead62e2f", "page": 10 } ] }